222 related articles for article (PubMed ID: 12743131)
1. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.
Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ
Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236
[TBL] [Abstract][Full Text] [Related]
4. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
5. OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.
Madiyalakan R; Yang R; Schultes BC; Baum RP; Noujaim AA
Hybridoma; 1997 Feb; 16(1):41-5. PubMed ID: 9085127
[TBL] [Abstract][Full Text] [Related]
6. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
7. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
8. Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y
Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
[TBL] [Abstract][Full Text] [Related]
9. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
10. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
11. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
13. Use of monoclonal antibodies in the treatment of ovarian cancer.
Mabuchi S; Morishige K; Kimura T
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):3-8. PubMed ID: 19770762
[TBL] [Abstract][Full Text] [Related]
14. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
15. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
17. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
19. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
[TBL] [Abstract][Full Text] [Related]
20. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
